272-50-4 | 5H-Pyrrolo[3,2-d]pyrimidine

Packsize	Purity	Availability	Price	Discounted Price
100mg	98%	in stock	$17.00	$12.00
250mg	98%	in stock	$28.00	$20.00
1g	98%	in stock	$96.00	$68.00

Description

• Catalog Number: AF32752
• Chemical Name: 5H-Pyrrolo[3,2-d]pyrimidine
• CAS Number: 272-50-4
• Molecular Formula: C6H5N3
• Molecular Weight: 119.124
• MDL Number: MFCD09834826
• SMILES: c1ncc2c(n1)cc[nH]2

Computed Properties

• Complexity: 105
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 9
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 1
• XLogP3: 0.4

Literature

• Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy.

  Bioorganic & medicinal chemistry 20121015

• Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena.

  Bioorganic chemistry 20121001

• Ethyl 3-(4-chloro-phen-yl)-2-(dipentyl-amino)-4-oxo-5-phenyl-4,5-dihydro-3H-pyrrolo-[3,2-d]pyrimidine-7-carboxyl-ate.

  Acta crystallographica. Section E, Structure reports online 20120701

• Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.

  European journal of medicinal chemistry 20120601

• A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis.

  Cancer science 20120501

• Design and synthesis of pyrrolo[3,2-d]pyrimidine human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors: exploration of novel back-pocket binders.

  Journal of medicinal chemistry 20120426

• Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

  Molecular cancer therapeutics 20120401

• Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists.

  Bioorganic & medicinal chemistry letters 20120301

• Ethyl 2-diethyl-amino-4-oxo-3,5-diphenyl-4,5-dihydro-3H-pyrrolo-[3,2-d]pyrimidine-7-carboxyl-ate.

  Acta crystallographica. Section E, Structure reports online 20120101

• Pyrrolo[3,2-d]pyrimidine derivatives as type II kinase insert domain receptor (KDR) inhibitors: CoMFA and CoMSIA studies.

  International journal of molecular sciences 20120101

• Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

  Journal of medicinal chemistry 20111208

• Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.

  European journal of medicinal chemistry 20111201

• Antitumor activity of novel pyrrolo[2,3-d]pyrimidin-4-ones.

  Drug and chemical toxicology 20110701

• Xanthate based radical cascade toward multicomponent formation of pyrrolopyrimidines.

  Molecules (Basel, Switzerland) 20110101

• A myosin V inhibitor based on privileged chemical scaffolds.

  Angewandte Chemie (International ed. in English) 20101102

• Design, synthesis, and evaluation of an α-tocopherol analogue as a mitochondrial antioxidant.

  Bioorganic & medicinal chemistry 20101101

• Design, synthesis, and evaluation of 5-methyl-4-phenoxy-5H-pyrrolo[3,2-d]pyrimidine derivatives: novel VEGFR2 kinase inhibitors binding to inactive kinase conformation.

  Bioorganic & medicinal chemistry 20101015

• N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases.

  Bioorganic & medicinal chemistry 20101015

• Polarizable water molecules in ligand-macromolecule recognition. Impact on the relative affinities of competing pyrrolopyrimidine inhibitors for FAK kinase.

  Journal of the American Chemical Society 20100317

• Combined pharmacophore modeling, docking, and 3D QSAR studies of ABCB1 and ABCC1 transporter inhibitors.

  ChemMedChem 20091101

• Novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent and orally active STAT6 inhibitors.

  Bioorganic & medicinal chemistry 20091001

• Synthesis and antiproliferative activity of 2,4-disubstituted 6-aryl-7H-pyrrolo[3,2-d]pyrimidin-7-one 5-oxides.

  Bioorganic & medicinal chemistry 20090715

• Effect of cathepsin K inhibitors on bone resorption.

  Journal of medicinal chemistry 20080911

• Deciphering deazapurine biosynthesis: pathway for pyrrolopyrimidine nucleosides toyocamycin and sangivamycin.

  Chemistry & biology 20080825

• Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.

  Journal of medicinal chemistry 20030703